drugset / Trial / NCT04540692
Evaluation of Sequencing of Anthracyclines and Taxanes for Locally Advanced HER2-negative Breast Cancer
Phase 3
Recruiting
444 enrolled
Latin American Cooperative Oncology Group
Grupo Brasileiro de Estudos do Câncer de Mama (GBECAM) · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Phase III randomized clinical trial evaluating the sequencing of anthracyclines and taxanes in neoadjuvant therapy for locally advanced HER2-negative breast cancer.
Timeline
- Start
- 2021-01-12
- Primary completion
- 2026-04
- Completion
- 2030-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Cyclophosphamide | Other / unclassified | 600 mg/m2 | Intravenous |
| Subject | Docetaxel | Small molecule | 75 mg/m2 | Intravenous |
| Subject | Docetaxel | Small molecule | 100 mg/m2 | Intravenous |
| Comparator | Doxorubicin | Other / unclassified | 60 mg/m2 | — |
| Subject | Paclitaxel | Small molecule | 80 mg/m2 | — |